Immunotherapy for head and neck cancer

Oral Oncology

Volumn 45, Issue 9, 2009, Pages 747-751

  Davidson, H Carter ^a   Leibowitz, Michael S ^a   Lopez Albaitero, Andres ^a   Ferris, Robert L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; Cytokines; Dendritic cells; Immunotherapy; Tumor antigens

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOLOGOUS TUMOR CELL NEW CASTLE DISEASE VIRUS VACCINE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DNA VACCINE; GROWTH FACTOR RECEPTOR; LISTERIOLYSIN O; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; NAKED DNA; NEWCASTLE DISEASE VACCINE; PANITUMUMAB; PEPTIDE VACCINE; PROTEIN E7; PROTEIN P53; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL TRIAL; CYTOLYSIS; DISEASE CONTROL; DISTANT METASTASIS; DRUG EFFICACY; DRUG MECHANISM; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VIVO STUDY; MINIMAL RESIDUAL DISEASE; NONVIRAL GENE DELIVERY SYSTEM; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; VACCINATION;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; PEPTIDES; RECEPTORS, GROWTH FACTOR; TREATMENT OUTCOME; VACCINES, DNA;

EID: 68949207887     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.02.009     Document Type: Review

References (51)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27 10 (2005) 843-850
3. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
4. Vikram B., Strong E.W., Shah J.P., and Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg 6 3 (1984) 734-737
5. Ferris R.L., Whiteside T.L., and Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12 13 (2006) 3890-3895
6. Mandruzzato S., Brasseur F., Andry G., Boon T., and van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186 5 (1997) 785-793
7. Kass E.S., Greiner J.W., Kantor J.A., et al. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 62 17 (2002) 5049-5057
8. Kienstra M.A., Neel H.B., Strome S.E., and Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25 6 (2003) 457-463
9. Ferris R.L. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?. ORL J Otorhinolaryngol Relat Spec 66 6 (2004) 332-340
10. Modjtahedi H., Moscatello D.K., Box G., et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105 2 (2003) 273-280
11. Balz V., Scheckenbach K., Gotte K., Bockmuhl U., Petersen I., and Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63 6 (2003) 1188-1191
12. Patel S., Wang F.H., Whiteside T.L., and Kasid U. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol 33 3 (1997) 197-203
13. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 9 (2000) 709-720
14. Albers A., Abe K., Hunt J., et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65 23 (2005) 11146-11155
15. Chen G., Shankar P., Lange C., et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 98 1 (2001) 156-164
16. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
17. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 11 (2008) 1116-1127
18. Monji M., Senju S., Nakatsura T., et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 294 3 (2002) 734-741
19. Caponigro F., Formato R., Caraglia M., Normanno N., and Iaffaioli R.V. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17 3 (2005) 212-217
20. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 52 5 (2003) 342-346
21. Modjtahedi H., Eccles S., Sandle J., Box G., Titley J., and Dean C. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54 7 (1994) 1695-1701
22. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7 5 (2001) 1204-1213
23. Pfister D.G., Laurie S.A., Weinstein G.S., et al. American society of clinical oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24 22 (2006) 3693-3704
24. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Clark JR, Goguen L, et al. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 2008;26(May 20 Suppl):abstr 6007.
25. Kim S., Grandis J.R., Rinaldo A., Takes R.P., and Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30 5 (2008) 667-674
26. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 3 (2003) 1581-1587
27. Lopez-Albaitero A., and Ferris R.L. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133 12 (2007) 1277-1281
28. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 11 (2008) 1789-1796
29. Dhodapkar K.M., Krasovsky J., Williamson B., and Dhodapkar M.V. Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195 1 (2002) 125-133
30. Banerjee D., Matthews P., Matayeva E., Kaufman J.L., Steinman R.M., and Dhodapkar K.M. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcγRs on human dendritic cells. J Immunother 31 2 (2008) 113-120
31. Ferris R., Whiteside T.L., and Ferrone S. Clinical significance of downregulated antigen processing machinery in head and neck cancer. Clin Cancer Res 12 13 (2006) 3890-3895
32. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 21 (2003) 3940-3947
33. Kushner B.H., Kramer K., and Cheung N.K. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19 22 (2001) 4189-4194
34. Zhang W., Gordon M., Schultheis A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25 24 (2007) 3712-3718
35. Lopez-Albaitero A, Lee S, Morgan S, et al. Role of polymorphic Fc gamma receptor (FcγR)IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009, in press.
36. Taylor RJ, Chan SL, Wood A, et al. FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2008.
37. Tomson T.T., Roden R.B., and Wu T.C. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 5 12 (2004) 1247-1261
38. Lu J., Wettstein P.J., Higashimoto Y., Appella E., and Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 166 12 (2001) 7063-7071
39. Becker-Hapak M., McAllister S.S., and Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods 24 3 (2001) 247-256
40. Devaraj K., Gillison M.L., and Wu T.C. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 14 5 (2003) 345-362
41. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
42. O'Malley Jr. B.W., Li D., McQuone S.J., and Ralston R. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 115 3 (2005) 391-404
43. Gilboa E., Nair S.K., and Lyerly H.K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46 2 (1998) 82-87
44. Sidransky D., Von Eschenbach A., Tsai Y.C., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252 5006 (1991) 706-709
45. Souders N.C., Sewell D.A., Pan Z.K., et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immunol 7 (2007) 2
46. Borysiewicz L.K., Fiander A., Nimako M., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 9014 (1996) 1523-1527
47. Karcher J., Dyckhoff G., Beckhove P., et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64 21 (2004) 8057-8061
48. Ferris R., Hunt J., and Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33 2 (2005) 113-133
49. Lopez-Albaitero A., Nayak J.V., Ogino T., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176 6 (2006) 3402-3409
50. Strauss L., Bergmann C., Gooding W., Johnson J.T., and Whiteside T.L. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 21 (2007) 6301-6311
51. Gabrilovich D.I., Chen H.L., Girgis K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 10 (1996) 1096-1103